Sharma Prakhar, Mishra Mayank, Dua Ruchi, Saini Lokesh Kumar, Sindhwani Girish
Department of Pulmonary, Sleep and Critical Care Medicine, AIIMS Rishikesh, Uttarakhand, India.
J Family Med Prim Care. 2022 Nov;11(11):6633-6639. doi: 10.4103/jfmpc.jfmpc_974_21. Epub 2022 Dec 16.
Coronavirus disease 2019 (COVID-19), caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is an acute respiratory disease that can lead to respiratory failure and death. Although anticipated that patients with chronic respiratory diseases would be at increased risk of SARS-CoV-2 infection and more severe presentations of COVID-19, it is striking that these diseases appear to be underrepresented in the comorbidities reported for patients with COVID-19. The first wave of COVID-19 has taught us important lessons concerning the enormous burden on the hospitals, shortage of beds, cross infections and transmissions, which we coped together. However, with the subsequent waves of COVID-19 or any other viral pandemic, to ensure that patients with respiratory illnesses receive adequate management for their diseases while minimizing their hospital visits for their own safety. Hence, we prepared an evidence-based summary to manage outpatients and inpatients suspected or diagnosed with COPD, asthma and ILD based on the experience of the first wave of COVID-19 and recommendations by expert societies and organizations.
2019冠状病毒病(COVID-19)由新型严重急性呼吸综合征冠状病毒2(SARS-CoV-2)引起,是一种可导致呼吸衰竭和死亡的急性呼吸道疾病。尽管预计慢性呼吸道疾病患者感染SARS-CoV-2的风险会增加,且COVID-19的表现会更严重,但令人惊讶的是,在报告的COVID-19患者合并症中,这些疾病的比例似乎较低。第一波COVID-19给我们带来了关于医院巨大负担、床位短缺、交叉感染和传播的重要教训,我们共同应对了这些问题。然而,对于随后的COVID-19浪潮或任何其他病毒大流行,为确保呼吸道疾病患者在保证自身安全的同时尽量减少医院就诊次数的情况下,能对其疾病进行充分治疗。因此,我们根据第一波COVID-19的经验以及专家协会和组织的建议,编写了一份循证摘要,以管理疑似或确诊患有慢性阻塞性肺疾病(COPD)、哮喘和间质性肺疾病(ILD)的门诊和住院患者。